[go: up one dir, main page]

HRP20210608T1 - Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije - Google Patents

Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije Download PDF

Info

Publication number
HRP20210608T1
HRP20210608T1 HRP20210608TT HRP20210608T HRP20210608T1 HR P20210608 T1 HRP20210608 T1 HR P20210608T1 HR P20210608T T HRP20210608T T HR P20210608TT HR P20210608 T HRP20210608 T HR P20210608T HR P20210608 T1 HRP20210608 T1 HR P20210608T1
Authority
HR
Croatia
Prior art keywords
seq
preparation
effective amount
additional
use according
Prior art date
Application number
HRP20210608TT
Other languages
English (en)
Inventor
Dan Barouch
Johanna Schuitemaker
Maria Grazia Pau
Danielle VAN MANEN
Frank TOMAKA
Jennifer Anne Hendriks
Original Assignee
Beth Israel Deaconess Medical Center, Inc.
Janssen Vaccines & Prevention B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center, Inc., Janssen Vaccines & Prevention B.V. filed Critical Beth Israel Deaconess Medical Center, Inc.
Publication of HRP20210608T1 publication Critical patent/HRP20210608T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Claims (15)

1. Kombinacija cjepiva, naznačena time, da je za uporabu u postupku induciranja imunosnog odgovora protiv virusa humane imunodeficijencije (HIV) kod pojedinca, pri čemu navedena kombinacija sadrži: (i) prvi pripravak koji sadrži imunogenetski učinkovitu količinu jednog ili više adenovirusnih 26 vektora (rAd26) koji kodiraju HIV antigene polipeptide s aminokiselinskim sljedovima od SEQ ID NO: 1, SEQ ID NO: 3 i SEQ ID NO: 4, i farmaceutski prihvatljiv nosač; (ii) drugi pripravak koji sadrži imunogenetski učinkovitu količinu izoliranog HIV glikoproteina ovojnice s aminokiselinskim slijedom od SEQ ID NO: 5 ili SEQ ID NO: 6, pomoćno sredstvo, i farmaceutski prihvatljiv nosač; i (iii) imunogenetski učinkovitu količinu jednog ili više dodatnih rAd26 vektora koji kodiraju HIV antigene polipeptide s aminokiselinskim sljedovima od SEQ ID NO: 1, SEQ ID NO: 3 i SEQ ID NO: 4, pri čemu se prvi pripravak daje za primarnu imunizaciju i drugi pripravak se daje za dodatnu pojačanu imunizaciju, i imunogenetski učinkovita količina dodatnih rAd26 vektora, nalazi se u drugom pripravku ili u trećem pripravku koji se daje zajedno s drugim pripravkom za dodatnu pojačanu imunizaciju.
2. Kombinacija cjepiva za uporabu prema patentnom zahtjevu 1, naznačena time, da se imunogenetski učinkovita količina jednog ili više dodatnih rAd26 vektora nalazi u trećem pripravku.
3. Kombinacija cjepiva za uporabu prema patentnom zahtjevu 1 ili 2, naznačena time, da se kod pomoćnog sredstva radi o aluminijevom fosfatu ili pomoćnom sredstvu na bazi saponina.
4. Kombinacija cjepiva za uporabu prema patentnom zahtjevu 3, naznačena time, da pomoćno sredstvo jest aluminijev fosfat.
5. Kombinacija cjepiva za uporabu prema bilo kojem od patentnih zahtjeva 1 do 4, naznačena time, da izolirani HIV glikoprotein ovojnice posjeduje aminokiselinski slijed od SEQ ID NO: 5.
6. Kombinacija cjepiva za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačena time, da spomenuti imunosni odgovor jest zaštitni imunosni odgovor protiv HIV infekcije.
7. Komplet, naznačen time, da obuhvaća kombinaciju cjepiva za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5.
8. Kombinacija cjepiva, naznačena time, da je za uporabu u induciranju imunosnog odgovora protiv virusa humane imunodeficijencije (HIV) kod pojedinca, pri čemu navedena kombinacija cjepiva sadrži: (i) prvi pripravak koji sadrži imunogenetski učinkovitu količinu jednog ili više adenovirusnih 26 vektora (rAd26) koji kodiraju HIV antigene polipeptide s aminokiselinskim sljedovima od SEQ ID NO: 1, SEQ ID NO: 3 i SEQ ID NO: 4, i farmaceutski prihvatljiv nosač; (ii) drugi pripravak koji sadrži imunogenetski učinkovitu količinu izoliranog HIV glikoproteina ovojnice s aminokiselinskim slijedom od SEQ ID NO: 5, farmaceutski prihvatljiv nosač, i pomoćno sredstvo, gdje je pomoćno sredstvo aluminijev fosfat ili pomoćno sredstvo na bazi saponina; i (iii) treći pripravak koji sadrži imunogenetski učinkovitu količinu jednog ili više dodatnih rAd26 vektora koji kodiraju HIV antigene polipeptide s aminokiselinskim sljedovima od SEQ ID NO: 1, SEQ ID NO: 3 i SEQ ID NO: 4, pri čemu se prvi pripravak daje za primarnu imunizaciju, a drugi pripravak se daje zajedno s trećim pripravkom za dodatnu pojačanu imunizaciju.
9. Kombinacija cjepiva za uporabu prema patentnom zahtjevu 8, naznačena time, da pomoćno sredstvo jest aluminijev fosfat.
10. Prvi pripravak, naznačen time, da sadrži imunogenetski učinkovitu količinu jednog ili više adenovirusnih 26 vektora (rAd26) koji kodiraju HIV antigene polipeptide s aminokiselinskim sljedovima od SEQ ID NO: 1, SEQ ID NO: 3 i SEQ ID NO: 4, i farmaceutski prihvatljiv nosač, za uporabu s drugim pripravkom koji sadrži imunogenetski učinkovitu količinu izoliranog HIV glikoproteina ovojnice s aminokiselinskim slijedom od SEQ ID NO: 5 ili SEQ ID NO: 6, pomoćno sredstvo, i farmaceutski prihvatljiv nosač, i imunogenetski učinkovitu količinu jednog ili više dodatnih rAd26 vektora koji kodiraju HIV antigene polipeptide s aminokiselinskim sljedovima od SEQ ID NO: 1, SEQ ID NO: 3 i SEQ ID NO: 4, u postupku induciranja imunosnog odgovora protiv virusa humane imunodeficijencije (HIV) kod pojedinca, gdje navedeni postupak obuhvaća davanje navedenog prvog pripravka za primarnu imunizaciju, davanje navedenog drugog pripravka za dodatnu pojačanu imunizaciju, i davanje imunogenetski učinkovite količine dodatnih rAd26 vektora, pri čemu se navedena imunogenetski učinkovita količina dodatnih rAd26 vektora nalazi u drugom pripravku ili u trećem pripravku koji se daje zajedno s drugim pripravkom za dodatnu pojačanu imunizaciju.
11. Drugi pripravak, naznačen time, da sadrži imunogenetski učinkovitu količinu izoliranog HIV glikoproteina ovojnice s aminokiselinskim slijedom od SEQ ID NO: 5 ili SEQ ID NO: 6, pomoćno sredstvo, i farmaceutski prihvatljiv nosač, za uporabu s prvim pripravkom koji sadrži imunogenetski učinkovitu količinu jednog ili više adenovirusnih 26 vektora (rAd26) koji kodiraju HIV antigene polipeptide s aminokiselinskim sljedovima od SEQ ID NO: 1, SEQ ID NO: 3 i SEQ ID NO: 4, i farmaceutski prihvatljiv nosač, i imunogenetski učinkovitu količinu jednog ili više dodatnih rAd26 vektora koji kodiraju HIV antigene polipeptide s aminokiselinskim sljedovima od SEQ ID NO: 1, SEQ ID NO: 3 i SEQ ID NO: 4, u postupku induciranja imunosnog odgovora protiv virusa humane imunodeficijencije (HIV) kod pojedinca, gdje navedeni postupak obuhvaća davanje navedenog prvog pripravka za primarnu imunizaciju, davanje navedenog drugog pripravka za dodatnu pojačanu imunizaciju, i davanje imunogenetski učinkovite količine dodatnih rAd26 vektora, pri čemu se navedena imunogenetski učinkovita količina dodatnih rAd26 vektora nalazi u drugom pripravku ili u trećem pripravku koji se daje zajedno s drugim pripravkom za dodatnu pojačanu imunizaciju.
12. Prvi pripravak za uporabu prema patentnom zahtjevu 10 ili drugi pripravak za uporabu prema patentnom zahtjevu 11, naznačeni time, da se imunogenetski učinkovita količina jednog ili više dodatnih rAd26 vektora nalazi u trećem pripravku.
13. Prvi pripravak za uporabu prema patentnom zahtjevu 10 ili 12, ili drugi pripravak za uporabu prema patentnom zahtjevu 11 ili 12, naznačeni time, da se kod pomoćnog sredstva radi o aluminijevom fosfatu ili pomoćnom sredstvu na bazi saponina, pri čemu je poželjno da pomoćno sredstvo bude aluminijev fosfat.
14. Prvi pripravak za uporabu prema patentnom zahtjevu 10 ili 12 ili 13, ili drugi pripravak za uporabu prema patentnom zahtjevu 11 ili 12 ili 13, naznačeni time, da izolirani HIV glikoprotein ovojnice posjeduje aminokiselinski slijed od SEQ ID NO: 5.
15. Prvi pripravak za uporabu prema bilo kojem od patentnih zahtjeva 10 i 12 do 14, ili drugi pripravak za uporabu prema bilo kojem od patentnih zahtjeva 11 i 12 do 14, naznačeni time, da spomenuti imunosni odgovor jest zaštitni imunosni odgovor protiv HIV infekcije.
HRP20210608TT 2014-09-26 2021-04-16 Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije HRP20210608T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462056059P 2014-09-26 2014-09-26
EP15845233.4A EP3197489B1 (en) 2014-09-26 2015-09-24 Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
PCT/US2015/051891 WO2016049287A1 (en) 2014-09-26 2015-09-24 Methods and compositions for inducing protective immunity against human immunodeficiency virus infection

Publications (1)

Publication Number Publication Date
HRP20210608T1 true HRP20210608T1 (hr) 2021-06-11

Family

ID=55581992

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210608TT HRP20210608T1 (hr) 2014-09-26 2021-04-16 Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije

Country Status (29)

Country Link
US (4) US10137191B2 (hr)
EP (2) EP3868398A1 (hr)
JP (2) JP6438575B2 (hr)
KR (2) KR101971808B1 (hr)
CN (2) CN112121160A (hr)
AP (1) AP2017009846A0 (hr)
AU (2) AU2015320574B2 (hr)
BR (1) BR112017005917A2 (hr)
CA (1) CA2961024A1 (hr)
CY (1) CY1124254T1 (hr)
DK (1) DK3197489T3 (hr)
EA (2) EA037583B1 (hr)
ES (1) ES2865150T3 (hr)
HR (1) HRP20210608T1 (hr)
HU (1) HUE053585T2 (hr)
IL (2) IL251114B (hr)
LT (1) LT3197489T (hr)
MA (1) MA40765B1 (hr)
MX (2) MX377967B (hr)
MY (1) MY175620A (hr)
PH (1) PH12017500449B1 (hr)
PL (1) PL3197489T3 (hr)
PT (1) PT3197489T (hr)
RS (1) RS61902B1 (hr)
SG (1) SG11201702110RA (hr)
SI (1) SI3197489T1 (hr)
SM (1) SMT202100244T1 (hr)
WO (1) WO2016049287A1 (hr)
ZA (1) ZA201702053B (hr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2865150T3 (es) 2014-09-26 2021-10-15 Beth Israel Deaconess Medical Ct Inc Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
CA3008542C (en) 2015-12-15 2020-06-02 Janssen Vaccines & Prevention B.V. Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
CA3014419A1 (en) 2016-02-16 2017-08-24 Geovax Inc. Multivalent hiv vaccine boost compositions and methods of use
MA45381A (fr) 2016-06-16 2021-04-21 Janssen Vaccines & Prevention Bv Formulation de vaccin contre le vih
CN110494159A (zh) * 2016-09-02 2019-11-22 扬森疫苗与预防公司 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法
IL294832A (en) 2016-09-15 2022-09-01 Janssen Vaccines Prevention B V Trimer stabilizing hiv envelope protein mutations
JP7272965B2 (ja) 2017-06-15 2023-05-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｉｖ抗原をコードするポックスウイルスベクターおよびその使用方法
CN110891601A (zh) 2017-07-19 2020-03-17 扬森疫苗与预防公司 三聚体稳定性hiv包膜蛋白突变
US20190022212A1 (en) 2017-07-21 2019-01-24 Beth Israel Deaconess Medical Center, Inc. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
WO2019055888A1 (en) * 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT
AU2019345942A1 (en) * 2018-09-25 2021-03-18 Janssen Vaccines & Prevention B.V. Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
WO2020214203A1 (en) * 2019-04-17 2020-10-22 The Wistar Institute Replication deficient adenoviral vectors for hiv vaccine applications
CN114828884A (zh) * 2019-05-22 2022-07-29 埃利克斯疗法公司 用于疫苗的剂量方案
WO2020237052A1 (en) * 2019-05-22 2020-11-26 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
CN114761041A (zh) 2019-07-16 2022-07-15 吉利德科学公司 Hiv疫苗及其制备和使用方法
WO2021089770A2 (en) 2019-11-07 2021-05-14 Janssen Vaccines & Prevention B.V. Protein purification
EP4277652A1 (en) 2021-01-14 2023-11-22 Gilead Sciences, Inc. Hiv vaccines and methods of using
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
NZ515582A (en) 1999-05-17 2003-11-28 Crucell Holland B Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
CA2384271A1 (en) 1999-09-17 2001-03-22 Joseph G. Sodroski Stabilized soluble glycoprotein trimers
KR20090057335A (ko) 2000-11-23 2009-06-04 버베리안 노딕 에이/에스 변형된 백시니아 앙카라 바이러스 변형체
WO2003004657A1 (en) 2001-07-05 2003-01-16 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
EP2345665A3 (en) 2001-12-04 2012-02-15 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
EP1497440B1 (en) 2002-04-25 2008-08-20 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
JP4495587B2 (ja) 2002-04-25 2010-07-07 クルセル ホランド ベー ヴェー 組換えアデノウイルスベクターおよびその使用
AU2003291402A1 (en) 2002-11-07 2004-06-03 Beth Israel Deaconess Medical Center MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
ES2416629T3 (es) 2002-12-03 2013-08-02 University Of Massachusetts Vacunas polivalentes de ADN de glicoproteína de VIH-1 primaria y procedimientos de vacunación
WO2004087201A2 (en) 2003-03-28 2004-10-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva virus expressing modified hiv envelope, gag, and pol genes
EP1667631A4 (en) * 2003-09-15 2010-04-14 Novartis Vaccines & Diagnostic COMBINATION PATHS FOR GENERATING IMMUNE RESPONSES
WO2005052119A2 (en) 2003-11-19 2005-06-09 Beth Israel Deaconess Medical Center Adjuvants of immune response
HUE033576T2 (en) 2004-01-23 2017-12-28 Msd Italia Srl Chimpanzee adenovirus vaccine carriers
WO2006002079A2 (en) 2004-06-15 2006-01-05 Progenics Pharmaceuticals, Inc. Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex
BRPI0513390A (pt) 2004-07-16 2008-05-06 Us Gov Health & Human Serv vacinas contra aids contendo construções de ácido nucléico cmv/r
DK1789438T3 (en) 2004-08-27 2015-07-20 Us Government Recombinant MVA viruses expressing MODIFIED env, gag and pol genes of HIV CLADE A / G, CLADE CLADE B AND C
EP1799836B1 (en) 2004-10-13 2010-12-22 Crucell Holland B.V. Improved adenoviral vectors and uses thereof
US20100015211A1 (en) * 2004-11-01 2010-01-21 Barnett Susan W Combination Approaches For Generating Immune Responses
US20100221241A1 (en) 2005-07-06 2010-09-02 University Of Maryland Biotechnology Institute Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
CN101969996A (zh) 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
WO2007149491A2 (en) 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Soluble stabilized trimeric hiv env proteins and uses thereof
CA2667358A1 (en) 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
WO2008140579A2 (en) 2006-11-17 2008-11-20 New York University Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope
PL2137210T3 (pl) 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
DK2358757T3 (da) 2008-11-18 2019-01-02 Beth Israel Deaconess Medical Ct Inc Antivirale vacciner med forbedret cellulær immunogenicitet
EP3385387B1 (en) 2009-02-02 2021-08-25 GlaxoSmithKline Biologicals SA Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
WO2011082087A2 (en) 2010-01-04 2011-07-07 Kj Biosciences, Llc Dps fusion proteins for use in vaccines and diagnostics
NZ600629A (en) 2010-01-28 2014-12-24 Bavarian Nordic As Vaccinia virus mutants containing the major genomic deletions of mva
EP2536829B1 (en) * 2010-02-15 2016-04-06 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
AU2011296065B2 (en) 2010-08-31 2016-01-28 International Aids Vaccine Initiative Human immunodeficiency virus (HIV)-neutralizing antibodies
AU2011316164B2 (en) 2010-10-15 2016-01-14 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) influenza vaccine
CA2821289C (en) 2010-12-14 2019-05-21 Nancy J. Sullivan Adenovirus serotype 26 and serotype 35 filovirus vaccines
US20140348791A1 (en) 2011-09-09 2014-11-27 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2766037A4 (en) 2011-10-12 2015-08-05 Scripps Research Inst HIV-1 GP-120 MINI-V3 LOOP AND USES THEREOF
WO2014047261A1 (en) 2012-09-19 2014-03-27 Beth Israel Deaconess Medical Center, Inc. Viruses associated with immunodeficiency and enteropathy and methods using same
US10106781B2 (en) 2012-11-16 2018-10-23 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and use thereof
EP2983686B1 (en) * 2013-01-07 2024-05-29 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
WO2014124301A1 (en) 2013-02-07 2014-08-14 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
EP3052132B1 (en) 2013-09-30 2020-07-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
CN103992396B (zh) * 2014-04-17 2017-03-29 南开大学 一种潜在的高效重组HIV‑1 CRF07‑BC gp140免疫原的制备方法
US10400015B2 (en) 2014-09-04 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
ES2865150T3 (es) 2014-09-26 2021-10-15 Beth Israel Deaconess Medical Ct Inc Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
CA3008542C (en) 2015-12-15 2020-06-02 Janssen Vaccines & Prevention B.V. Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
CN110494159A (zh) * 2016-09-02 2019-11-22 扬森疫苗与预防公司 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法

Also Published As

Publication number Publication date
IL251114B (en) 2019-05-30
IL265733B (en) 2021-05-31
KR20190042736A (ko) 2019-04-24
RS61902B1 (sr) 2021-06-30
MA40765B1 (fr) 2021-04-30
AU2015320574A1 (en) 2017-04-06
EP3197489B1 (en) 2021-02-17
PH12017500449A1 (en) 2017-07-31
JP6438575B2 (ja) 2018-12-12
MA40765A (fr) 2017-08-02
US20220096622A1 (en) 2022-03-31
MX377967B (es) 2025-03-10
AU2018267669B2 (en) 2020-03-05
MX2020013153A (es) 2021-02-18
PT3197489T (pt) 2021-04-30
MX2017003946A (es) 2017-12-20
WO2016049287A1 (en) 2016-03-31
EA202092521A1 (ru) 2021-05-31
PH12017500449B1 (en) 2022-07-22
EP3197489A4 (en) 2018-03-14
CY1124254T1 (el) 2022-07-22
ES2865150T3 (es) 2021-10-15
SG11201702110RA (en) 2017-04-27
US20160089432A1 (en) 2016-03-31
JP2017531627A (ja) 2017-10-26
ZA201702053B (en) 2021-09-29
SMT202100244T1 (it) 2021-07-12
US10471137B2 (en) 2019-11-12
AU2015320574B2 (en) 2018-12-06
KR102159626B1 (ko) 2020-09-25
HUE053585T2 (hu) 2021-07-28
AU2018267669A1 (en) 2018-12-13
JP6625716B2 (ja) 2019-12-25
IL265733A (en) 2019-05-30
US20200030437A1 (en) 2020-01-30
NZ730841A (en) 2021-08-27
DK3197489T3 (da) 2021-04-19
PL3197489T3 (pl) 2021-11-08
CN112121160A (zh) 2020-12-25
US11207400B2 (en) 2021-12-28
EP3868398A1 (en) 2021-08-25
LT3197489T (lt) 2021-07-26
SI3197489T1 (sl) 2021-08-31
AP2017009846A0 (en) 2017-03-31
BR112017005917A2 (pt) 2017-12-12
EA037583B1 (ru) 2021-04-16
EA201790717A1 (ru) 2018-02-28
CN106999571B (zh) 2020-10-02
MY175620A (en) 2020-07-02
IL251114A0 (en) 2017-04-30
EP3197489A1 (en) 2017-08-02
KR20170066454A (ko) 2017-06-14
CA2961024A1 (en) 2016-03-31
US20180250385A1 (en) 2018-09-06
JP2019038849A (ja) 2019-03-14
CN106999571A (zh) 2017-08-01
KR101971808B1 (ko) 2019-04-23
US10137191B2 (en) 2018-11-27

Similar Documents

Publication Publication Date Title
HRP20210608T1 (hr) Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
HRP20240163T1 (hr) Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom
WO2020063370A3 (zh) 免疫组合物及其制备方法与应用
PH12018502403A1 (en) Hiv vaccine formulation
UA114086C2 (xx) Імуногенна композиція глікопротеїну g вірусу hendra і/або nipah
MA44238B1 (fr) Procédés d'augmentation de l'efficacité d'un vaccin par administration d'un antagoniste d'il-4r
ZA202306479B (en) African swine fever (asf) virus vaccines
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
MX2021015465A (es) Vacuna para fiebre porcina africana.
Lowell et al. Back to the future: Immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain
BR112015032556A2 (pt) Proteína matriz (m) modificada de um vírus da estomatite vesicular (vsv); sequência de nucleotídeos que codifica uma proteína matriz modificada de um vírus da estomatite vesicular; vírus da estomatite vesicular recombinante (rvsv); vacina; vacina de combinação de preparação e reforço; kit; peptídeo isolado; sequências de nucleotídeos isoladas; uso da vacina; uso da vacina de combinação de preparação e reforço; método para induzir uma resposta imunológica em um indivíduo
JP2013518052A5 (hr)
BR112015017966A2 (pt) composições imunogênicas compreendendo vírus silificado e métodos de uso
CO6561819A2 (es) Vectores para vacunas y método para potenciar respuestas inmunes
BR112014015390A2 (pt) vírus da estomatite vesicular para vacinas iniciais e de reforço
CL2017003224A1 (es) Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante
JP2013545448A5 (hr)
RU2018123307A (ru) Вакцинация с использованием альфа3 домена mica/b для лечения рака
WO2018055535A3 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
AR076437A1 (es) Composicion inmunologica, equipo para provocar una respuesta inmune y metodo para provocar una respuesta inmune contra befv en un animal
JP2015525794A5 (hr)